tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tiziana Life Sciences CEO Increases Stake Amidst Ongoing Clinical Trials

Story Highlights
Tiziana Life Sciences CEO Increases Stake Amidst Ongoing Clinical Trials

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Tiziana Life Sciences ( (TLSA) ) is now available.

On September 9, 2025, Tiziana Life Sciences announced that CEO Ivor Elrifi purchased 14,848 shares of the company’s common stock at $1.65 per share, bringing his total holdings to 193,848 shares. This move underscores confidence in the company’s strategic direction, particularly its focus on developing intranasal foralumab, which is currently undergoing clinical trials for treating non-active secondary progressive multiple sclerosis. The announcement may positively impact stakeholder perceptions and signals strong internal belief in Tiziana’s innovative approach to immunotherapy.

The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company specializes in immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Tiziana aims to improve efficacy, safety, and tolerability of treatments through innovative nasal delivery methods, targeting neuroinflammatory and neurodegenerative diseases.

Average Trading Volume: 345,441

Technical Sentiment Signal: Buy

Current Market Cap: $185M

Learn more about TLSA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1